StockData
Cardiol Therapeutics Inc. logo

Cardiol Therapeutics Inc. (CRDL) stock

CRDLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 40-F on Mar 31, 2026Score 5/30
$0.86−0.02 (-2.28%)

Close on Nov 20, 2026Market cap $86.48MP/E –Yield –

Cardiol Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was C$14.02M, up 0.0% from the year before. The highest annual figure on record is C$18.96M in fiscal 2022.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025C$14.02M+0.0%
FY2024Dec 31, 2024C$14.01M-1.5%
FY2023Dec 31, 2023C$14.22M-25.0%
FY2022Dec 31, 2022C$18.96M+74.4%
FY2021Dec 31, 2021C$10.87M+2.5%
FY2020Dec 31, 2020C$10.60M–

More Cardiol Therapeutics figures

See a number that looks wrong?